Antibiotics & Treatment-Resistant Melanoma: A Stressful Subject
Eleonora Leucci, PhD, an MRA-funded investigator at KU Leuven (Belgium) has determined that some antibiotics may be able to slow, or even reverse, treatment resistance that melanoma develops to targeted therapies. If her preliminary findings are verified in the clinic, this would be a potent weapon in the melanoma treatment arsenal and a huge win for patients.
Asking the Tough Questions: Perspectives on Being a Caregiver, Self Care, & Mucosal Melanoma
“Being a caregiver can be the hardest job,” says Patricia Janiak. “Your loved one might be the one going through this – but we’re the ones who have to put on our brave face while always being a step ahead. We’re the ones who call the doctors, ask the tough questions, and when needed, we push the envelope.”
The Next Frontier of Combination Immunotherapy: Maximizing the Benefits & Reducing Harms
Every general knows that the best way to successfully win a war is to deploy multiple weapons with different targets. This strategy was first used in cancer to conquer childhood leukemias with combination chemotherapy and now is being put to the test in melanoma by combining multiple checkpoint inhibitors, as...
Mark, Stage 4 Melanoma, & a Personalized Vaccine Clinical Trial
The melanoma treatment landscape had dramatically changed in the time since Mark was first diagnosed with melanoma. New options had earned FDA approval and many other approaches were actively being tested in clinical trials. Hear Mark's story with a personalized vaccine made to help train his immune system to fight melanoma cells.
Practical Recommendations for Surviving and Thriving Despite Melanoma
4 August 2021 In Treatment
Most experts, including the National Cancer Institute, say that a person becomes a survivor from the moment they learn of their cancer diagnosis – for the rest of their life. Get practical tips and strategies to live well with melanoma based on an expert panel conversation, led by Dr. Sapna Patel of the University of Texas M.D. Anderson Cancer Center.
Full Sails Ahead: Immunotherapy Shows Continued Survival Benefit for Patients Facing Advanced Melanoma
After carefully following patients enrolled in Checkmate 067 over the last 6.5 years, he and the research team determined that 49% of patients treated with Opdivo + Yervoy were alive at 6.5 years and 77% of these patients remained treatment-free. This represents the longest reported median overall survival in a phase 3 melanoma clinical trial – ever.
Biomarkers: What They Are, Why They Matter, and Where They are Going
The melanoma treatment field has been rewarded recently with an abundance of riches. But all these exciting new treatment options for patients can also create complexity and confusion. Fortunately, help is on the way in the form of biomarkers — molecular or cellular indicators for whether a patient is likely to respond or is currently responding to their therapy, or whether they are likely to have a recurrence of their cancer.
Melanoma Research Alliance Announces 13 Dermatology Fellowship Award Recipients
The Melanoma Research Alliance, the largest non-profit funder of melanoma research, is proud to announce its 2021 Dermatology Fellowship Award recipients.
Setting the Groundwork for Patient-Centric 1st in Human Clinical Trial Funding Opportunities
From Michael Kaplan, MRA President & CEO: There is a reason the word “Alliance” is in our name! The Melanoma Research Alliance (MRA) knows that to achieve our mission of ending suffering and death due to melanoma, broad partnerships and collaborations are required. In this spirit, MRA entered its first partnership with...
2021 AACR and ASCO Melanoma Highlights
Over the last few months, thousands of scientists and physicians from around the globe gathered virtually for two of the largest cancer research conferences – AACR and ASCO. Melanoma research advances were showcased at both events and it’s an exciting time with numerous presentations of clinical trials for new melanoma treatments. Here we highlight some of the most exciting results from both conferences.